211 related articles for article (PubMed ID: 23307349)
41. An inhalable β₂-adrenoceptor ligand-directed guanidinylated chitosan carrier for targeted delivery of siRNA to lung.
Luo Y; Zhai X; Ma C; Sun P; Fu Z; Liu W; Xu J
J Control Release; 2012 Aug; 162(1):28-36. PubMed ID: 22698944
[TBL] [Abstract][Full Text] [Related]
42. Caveolae-Mediated Endocytosis Drives Robust siRNA Delivery of Polymeric Nanoparticles to Macrophages.
Song Y; Wu Y; Xu L; Jiang T; Tang C; Yin C
ACS Nano; 2021 May; 15(5):8267-8282. PubMed ID: 33915044
[TBL] [Abstract][Full Text] [Related]
43. Chitosan-based siRNA delivery systems.
Ragelle H; Vandermeulen G; Préat V
J Control Release; 2013 Nov; 172(1):207-218. PubMed ID: 23965281
[TBL] [Abstract][Full Text] [Related]
44. Biodistribution and pharmacokinetics of thiolated chitosan nanoparticles for oral delivery of insulin in vivo.
Sudhakar S; Chandran SV; Selvamurugan N; Nazeer RA
Int J Biol Macromol; 2020 May; 150():281-288. PubMed ID: 32057846
[TBL] [Abstract][Full Text] [Related]
45. Size-dependent absorption mechanism of polymeric nanoparticles for oral delivery of protein drugs.
He C; Yin L; Tang C; Yin C
Biomaterials; 2012 Nov; 33(33):8569-78. PubMed ID: 22906606
[TBL] [Abstract][Full Text] [Related]
46. Lyophilized insulin nanoparticles prepared from quaternized N-aryl derivatives of chitosan as a new strategy for oral delivery of insulin: in vitro, ex vivo and in vivo characterizations.
Mahjub R; Radmehr M; Dorkoosh FA; Ostad SN; Rafiee-Tehrani M
Drug Dev Ind Pharm; 2014 Dec; 40(12):1645-59. PubMed ID: 24093431
[TBL] [Abstract][Full Text] [Related]
47. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
[TBL] [Abstract][Full Text] [Related]
48. Lyophilisation and concentration of chitosan/siRNA polyplexes: Influence of buffer composition, oligonucleotide sequence, and hyaluronic acid coating.
Veilleux D; Gopalakrishna Panicker RK; Chevrier A; Biniecki K; Lavertu M; Buschmann MD
J Colloid Interface Sci; 2018 Feb; 512():335-345. PubMed ID: 29080529
[TBL] [Abstract][Full Text] [Related]
49. Impact of mucoadhesive polymeric nanoparticulate systems on oral bioavailability of a macromolecular model drug.
Fabiano A; Piras AM; Uccello-Barretta G; Balzano F; Cesari A; Testai L; Citi V; Zambito Y
Eur J Pharm Biopharm; 2018 Sep; 130():281-289. PubMed ID: 30006244
[TBL] [Abstract][Full Text] [Related]
50. Anti-Helicobacterpylori effectiveness and targeted delivery performance of amoxicillin-UCCs-2/TPP nanoparticles based on ureido-modified chitosan derivative.
Jing ZW; Luo M; Jia YY; Li C; Zhou SY; Mei QB; Zhang BL
Int J Biol Macromol; 2018 Aug; 115():367-374. PubMed ID: 29660462
[TBL] [Abstract][Full Text] [Related]
51. Enhanced gene delivery efficiency of cationic liposomes coated with PEGylated hyaluronic acid for anti P-glycoprotein siRNA: a potential candidate for overcoming multi-drug resistance.
Ran R; Liu Y; Gao H; Kuang Q; Zhang Q; Tang J; Huang K; Chen X; Zhang Z; He Q
Int J Pharm; 2014 Dec; 477(1-2):590-600. PubMed ID: 25448564
[TBL] [Abstract][Full Text] [Related]
52. TNF-α gene silencing using polymerized siRNA/thiolated glycol chitosan nanoparticles for rheumatoid arthritis.
Lee SJ; Lee A; Hwang SR; Park JS; Jang J; Huh MS; Jo DG; Yoon SY; Byun Y; Kim SH; Kwon IC; Youn I; Kim K
Mol Ther; 2014 Feb; 22(2):397-408. PubMed ID: 24145554
[TBL] [Abstract][Full Text] [Related]
53. Novel nanoparticles based on chitosan-dicarboxylate conjugates via tandem ionotropic/covalent crosslinking with tripolyphosphate and subsequent evaluation as drug delivery vehicles.
Dmour I; Taha MO
Int J Pharm; 2017 Aug; 529(1-2):15-31. PubMed ID: 28634140
[TBL] [Abstract][Full Text] [Related]
54. Efficient mucus permeation and tight junction opening by dissociable "mucus-inert" agent coated trimethyl chitosan nanoparticles for oral insulin delivery.
Liu M; Zhang J; Zhu X; Shan W; Li L; Zhong J; Zhang Z; Huang Y
J Control Release; 2016 Jan; 222():67-77. PubMed ID: 26686663
[TBL] [Abstract][Full Text] [Related]
55. Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for nasal and intradermal vaccination.
Verheul RJ; Slütter B; Bal SM; Bouwstra JA; Jiskoot W; Hennink WE
J Control Release; 2011 Nov; 156(1):46-52. PubMed ID: 21784113
[TBL] [Abstract][Full Text] [Related]
56. Efficient Peroral Delivery of Insulin via Vitamin B12 Modified Trimethyl Chitosan Nanoparticles.
Ke Z; Guo H; Zhu X; Jin Y; Huang Y
J Pharm Pharm Sci; 2015; 18(2):155-70. PubMed ID: 26158281
[TBL] [Abstract][Full Text] [Related]
57. [Chitosan-siRNA complex nanoparticles for gene silencing].
Liu X
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Feb; 27(1):97-101. PubMed ID: 20337033
[TBL] [Abstract][Full Text] [Related]
58. Preparation and evaluation of anti-neuroexcitation peptide (ANEP) loaded N-trimethyl chitosan chloride nanoparticles for brain-targeting.
Wang S; Jiang T; Ma M; Hu Y; Zhang J
Int J Pharm; 2010 Feb; 386(1-2):249-55. PubMed ID: 19900520
[TBL] [Abstract][Full Text] [Related]
59. Target-specific delivery of siRNA by stabilized calcium phosphate nanoparticles using dopa-hyaluronic acid conjugate.
Lee MS; Lee JE; Byun E; Kim NW; Lee K; Lee H; Sim SJ; Lee DS; Jeong JH
J Control Release; 2014 Oct; 192():122-30. PubMed ID: 24995950
[TBL] [Abstract][Full Text] [Related]
60. Improving the osteogenesis of rat mesenchymal stem cells by chitosan-based-microRNA nanoparticles.
Wu G; Feng C; Hui G; Wang Z; Tan J; Luo L; Xue P; Wang Q; Chen X
Carbohydr Polym; 2016 Mar; 138():49-58. PubMed ID: 26794737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
